Long-term results of surgical treatment of non-small cell lung cancer in patients over 75 years of age

Pawlak, Krystian; Gabryel, Piotr; Kujawska, Anna; Kasprzyk, Mariusz; Piwkowski, Cezary; Kuffel, Błażej; Dyszkiewicz, Wojciech

doi:10.5114/kitp.2018.76470

Cited by 12 publications

(14 citation statements)

References 24 publications

(50 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Radiotherapy and chemotherapy treatments remain the common curative therapy options for patients with NSCLC. Despite the great advance in the therapy options, including immunotherapy and targeted therapies, for this disease the clinical outcomes of patients with NSCLC are slightly improved because of recurrence and metastasis 2,3. Hence, it is very important to identify the molecular mechanisms behind the metastasis of NSCLC and explore the potential therapeutic targets for NSCLC.…”

Section: Introductionmentioning

confidence: 99%

<p>miRNA-101-5p inhibits the growth and aggressiveness of NSCLC cells through targeting CXCL6</p>

Chen¹,

Liú²,

Zhang³

et al. 2019

OTT

View full text Add to dashboard Cite

BackgroundThe purpose of this study is to explore the potential biological roles of miR-101-5p in the progression of non-small-cell lung carcinoma (NSCLC).MethodsThe levels of miR-101-5p and chemokine (C-X-C motif) ligand 6 (CXCL6) in NSCLC tissues and cells were detected using the quantitative real-time PCR (qRT-PCR) assay. Proliferation, colony formation, migration and invasion assays were conducted using miR-101-5p-transfected NSCLC cells in vitro. The expression of CXCL6 was measured using immunofluorescence assay. Xenograft model and lung metastasis model were constructed to further reveal the precise roles of miR-101-5p in the lung metastasis and growth of NSCLC cells in vivo.ResultsmiR-101-5p was underregulated in NSCLC tissues when compared with that in the normal controls. The levels of miR-101-5p were lower in NSCLC cells (H1975, A549, HCC827 and H1650) than in non-tumorigenic human bronchial epithelial cells (BEAS-2B). Overregulation of miR-101-5p restrained the aggressiveness phenotypes of NSCLC cells in vitro. Furthermore, overregulation of miR-101-5p reduced the tumor growth and pulmonary metastasis of NSCLC cells in vivo. CXCL6 was the target gene of miR-101-5p in NSCLC. The mRNA levels of CXCL6 were negatively associated with the levels of miR-101-5p in NSCLC tissues. Finally, the rescue experiments suggested that the inhibitory role of miR-101-5p was mediated by regulating the expression of CXCL6 in NSCLC.ConclusionThese findings indicated that overregulation of miR-101-5p restrained the progression of NSCLC cells by targeting CXCL6 and might function as a potential therapeutic target for NSCLC.

show abstract

Section: Introductionmentioning

confidence: 99%

<p>miRNA-101-5p inhibits the growth and aggressiveness of NSCLC cells through targeting CXCL6</p>

Chen¹,

Liú²,

Zhang³

et al. 2019

OTT

View full text Add to dashboard Cite

show abstract

“…Despite the comprehensive treatment strategies, including surgery, radiotherapy, immunotherapy and targeted therapies, the clinical outcomes of patients with NSCLC are slightly improved. However, due to recurrence and metastasis, NSCLC is still considered to be a global challenge (4,5). Similar to other cancer cell types, NSCLC cells are character-ized by their sustained proliferation (6).…”

Section: Introductionmentioning

confidence: 99%

IL‑21/IL‑21R inhibit tumor growth and invasion in non‑small cell lung cancer cells via suppressing Wnt/β‑catenin signaling and PD‑L1 expression

et al. 2019

View full text Add to dashboard Cite

Lung cancer is considered to be one of the world's deadliest diseases, with non-small cell lung cancer (NSCLC) accounting for 85% of all lung cancer cases. The present study aimed to investigate the role and underlying mechanisms of interleukin-21 (IL-21), and its receptor IL-21R, in NSCLC. Lung tissues and blood samples of NSCLC were used to measure IL-21, IL-21R and programmed death 1 ligand 1 (PD-L1) expression using ELISA, western blot and immunohistochemistry analyses. Following treatment with different doses of IL-21, the proliferation, invasion and migration of human NSCLC cell line A549 was evaluated using a cell counting kit-8, colony formation, Transwell and scratch wound healing assays, respectively. Additionally, IL-21R and PD-L1 expression in A549 cells was detected using western blot analysis and immunofluorescence. IL-21R silencing was subsequently used to investigate its effects in cell proliferation, invasion and migration. PD-L1, IL-1β and tumor necrosis factor α (TNF-α) expression were measured. Finally, Wnt/β-catenin signaling expression was evaluated using western blot analysis following treatment with IL-21. Cells were then treated with lithium chloride (LiCl), which is an agonist of Wnt/β-catenin signaling, and the levels of PD-L1, IL-1β and TNF-α were detected. The results revealed that IL-21 and IL-21R expression in the lung tissues and blood samples of patients with NSCLC were decreased, while PD-L1 expression was increased, compared with normal tissues or healthy controls. Treatment of A549 cells with IL-21 upregulated IL-21R expression, downregulated PD-L1 and inhibited cell growth and metastasis in a dose-dependent manner. Following IL-21R silencing, the effects of IL-21 treatment were reversed, suggesting that IL-21 acted on A549 cells through binding to IL-21R. In addition, the results demonstrated that IL-21 treatment reduced the expression levels of proteins associated with the Wnt/β-catenin signaling, whereas activation of Wnt/β-catenin signaling with the LiCl agonist upregulated PD-L1, IL-1β and TNF-α expression. In conclusion, the IL-21/IL-21R axis reduced the growth and invasion of NSCLC cells via inhibiting Wnt/β-catenin signaling and PD-L1 expression. The present results may provide a novel molecular target for NSCLC diagnosis and therapy.

show abstract

“…In previous studies, age has been recognized as a prognostic factor for NSCLC using cut-off values of 80, 75, 70, and even 50 years (16)(17)(18)(19). In the present study, age <65 years was associated with a longer survival time in both univariate (HR = 1.42, 95% CI = 1.18-1.73) and multivariate (HR = 1.23, 95% CI = 1.00-1.52) analyses.…”

Section: Discussionmentioning

confidence: 99%

Development of a Survival Prognostic Model for Non-small Cell Lung Cancer

Zhang

et al. 2020

Front. Oncol.

View full text Add to dashboard Cite

Lung cancer is a leading cause of cancer-related death, and >80% of lung cancer diagnoses are non-small-cell lung cancer (NSCLC). However, when using current staging and prognostic indices, the prognosis can vary significantly. In the present study, we calculated a prognostic index for predicting overall survival (OS) in NSCLC patients. The data of 545 NSCLC patients were retrospectively reviewed. Univariate and multivariate Cox proportional hazards regression analyses were performed to evaluate the prognostic value of clinicopathological factors. Age (hazard ratio [HR] = 1.25, 95% confidence interval [CI] = 1.02-1.54), TNM stage (III, HR = 1.64, 95% CI = 1.08-2.48; IV, HR = 2.33, 95% CI = 1.48-3.69), lung lobectomy (HR = 1.96, 95% CI = 1.45-2.66), chemotherapy (HR = 1.42, 95% CI = 1.15-1.74), and pretreatment hemoglobin level (HR = 1.61, 95% CI = 1.28-2.02) were independent prognosticators. A prognostic index for NSCLC (PInscl, 0-6 points) was calculated based on age (≥65 years, 1 point), tumor-node-metastasis (TNM) stage (III, 1 point; IV, 2 points), lung lobectomy (no, 1 point), chemotherapy (no, 1 point), and pretreatment hemoglobin level (low, 1 point). In comparison with the "PInscl = 0" subgroup (survival time = 2.71 ± 1.86 years), the "PInscl = 2" subgroup (survival time = 1.86 ± 1.24 years), "PInscl = 3" subgroup (survival time = 1.45 ± 1.07 years), "PInscl = 4" subgroup (survival time = 1.17 ± 1.06 years), "PInscl = 5" subgroup (survival time = 0.81 ± 0.78 years), and "PInscl = 6" subgroup (survival time = 0.65 ± 0.56 years) exhibited significantly shorter survival times. Kaplan-Meier survival analysis showed that patients with higher PInscl scores had poorer OS than those with lower scores (log-rank test: χ 2 = 155.82, P < 0.0001). The area under the curve of PInscl for predicting the 1-year OS was 0.73 (95 % CI = 0.69-0.77, P < 0.001), and the PInscl had a better diagnostic performance than the Karnofsky performance status or TNM stage (P < 0.01). In conclusion, the PInscl, which is calculated from age, TNM stage, lung lobectomy, chemotherapy, and pretreatment hemoglobin level, significantly predicted OS in NSCLC patients.

show abstract

Long-term results of surgical treatment of non-small cell lung cancer in patients over 75 years of age

Cited by 12 publications

References 24 publications

<p>miRNA-101-5p inhibits the growth and aggressiveness of NSCLC cells through targeting CXCL6</p>

<p>miRNA-101-5p inhibits the growth and aggressiveness of NSCLC cells through targeting CXCL6</p>

IL‑21/IL‑21R inhibit tumor growth and invasion in non‑small cell lung cancer cells via suppressing Wnt/β‑catenin signaling and PD‑L1 expression

Development of a Survival Prognostic Model for Non-small Cell Lung Cancer

Contact Info

Product

Resources

About